Share your videos with the world

Sign Up | Log In | Help  

Hint: ClipMoon is not responsible for the content of this page. These contents are from private users!

  Procoralan® Reduces Heart Failure Death, Hospitalisation Ris  
Average ( 0 votes)
Not yet rated
Please sign up
and login to rate this video.!

The largest-ever morbi-mortality study of treatments for chronic heart failure has shown that adding the specific heart rate lowering agent Procoralan® (ivabradine) to standard therapy significantly reduces the risk of death and hospitalisation for heart failure.1 Results from this new study, SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial), were presented today at the European Society of Cardiology1 in Stockholm and published in The Lancet.2 To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/shift/44195/
Added on 01-09-2010 by MultiVuVideos

PHP Scripts and Service
 

Video Details //

 
Runtime: 5m45s | Views: 6120 | Comments: 0

Categories:  News and Politics 
 

User Details //

 
Videos: 5590 | Favorites: 0 | Friends: 0
User Name:  MultiVuVideos

  Share Details //  
Video URL:  
(E-mail or link it)

Embeddable Player:
(Put this video on your website. Works on Friendster, eBay, Blogger, MySpace and many more sites!)

Thumbnail URL:
Preview:
(Put this thumbnail on your website, blog or in your forum posts.)


Comment on this video:
Comments (0):
Please help keep this site FUN, CLEAN, and REAL.
Please sign up and login to flag or comment this video.!

    
   Other Videos  

< PREV
NOW PLAYING

NEXT >

 
Featured Videos
 
by river6
Runtime: 1m2s
Views: 834
Comments: 1
by Mike
Runtime: 4m5s
Views: 1176
Comments: 2
by tory
Runtime: 1m5s
Views: 29
Comments: 1
by padani
Runtime: 1m10s
Views: 551
Comments: 2
Runtime: 2m24s
Views: 18549
Comments: 3
 
PHP Scripts and Custom Service

 

 

About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2025 ClipMoon. All rights reserved.